Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Minerva Neurosciences, Inc. (NERV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.83, with a market capitalisation of $191.47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.93 to $12.46. This page covers its latest market performance, valuation, price trends and company information.
$191.47M | |
$4.01 | |
$126.72 | |
$1.15 | |
$4.01 | |
273.96K | |
258.02K | |
-- | |
$12.46 | |
$1.93 | |
-- | |
-- |
Minerva Neurosciences, Inc. (NERV) is trading at $4.11 in pre-market trading as of 2026-09-15 23:31:00, up 2.52% ($0.10) from the previous close of $4.01
Pre-market trading shows how investors are pricing NERV before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Minerva Neurosciences, Inc. (NERV) moved from $4.43 to $3.83, representing a decline of 13.63% ($0.60).
The stock traded between $3.57 and $4.80 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 128.14 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 18.0%
NERV is currently trading at $3.83, placing it 18.0% of the way from its 52-week low of $1.93 to its 52-week high of $12.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Minerva Neurosciences, Inc. (NERV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.